Tanabe Seiyaku Company, Limited

Takao Mori

Tetsuya Tosa

Ichiro Chibata

Motoki Fujimura

Taizo Watanabe

Eiji Takahashi

Takeji Shibatani

Masakatsu Furui

Toshiyuki Furutani

Akio Nakao

Yuhsi Matuo

Katsuhiko Nakamichi

Atsuhiko Tsujimura

Ryujiro Sano

There is disclosed a process for preparing D-mandelic acid comprising the steps of: (1) treating racemic mandelic acid with a culture broth, cells or treated cells of a microorganism having ability of converting L-mandelic acid into benzoylformic acid.

Process for producing D-mandelic acid from benzoylformic acid

There is disclosed a process for preparing optically active 3-phenylglycidic acid ester compound, which comprises permitting a culture broth, cells or treated cells of a microorganism having an ability of stereoselectively hydrolyzing a (2R, 3S)-3-phenylglycidic acid ester compound to act on a racemic 3-phenylglycidic acid ester compound which may also have a substituent on the phenyl group, thereby hydrolyzing the (2R, 3S) optically active isomer and separating and collecting the (2S, 3R) antipode from the reaction mixture.

Process for preparing optically active 3-phenylglycidic acid esters

An immobilized enzyme having reversible solubility is prepared by attaching an enzyme to a copolymer of two of more monomers selected from the group consisting of acrylic acid or an alkyl ester thereof, methacrylic acid or alkyl ester or dialkylamino-alkyl ester thereof, and a vinylpyridine derivative of the general formula [U]: ##STR1## wherein R is an alkyl. Preferred capolymers are methacrylic acid-alkyl methacrylate-alkyl acrylate, methacrylic acid-alkyl methacrylate, alkyl acrylate-methacrylic acid, alkyl acrylate-methacrylic acid-alkyl acrylate, alkyl acrylate-methacrylic acid-2-methyl-5-vinylpyridine and dialkylaminoalkyl methacrylate-alkyl methacrylate. The immobilized enzyme has a high activity and can dissolve even in an organic solvent or in a solution containing an organic solvent.

Immobilized enzyme having reversible solubility

An immobilized aminoacylase is prepared by bonding aminoacylase to a water-insoluble porous anion exchanger such as a porous phenolic resin, porous styrene resin, porous silica or porous glass having anion exchange groups and treating the bonded amino-acylase with a crosslinking agent such as an aliphatic dialdehyde. The porous anion exchanger preferably has a pore size of about 150.degree. to 3,000 A.degree., pore volume of about 0.3 to 1.0 m.sup.1 /g, specific surface area of about 10 to 150 m.sup.2 /g and particle size of above 0.1 to 1.2 mm. Preferred anion exchangers are trimethylammonium-introduced styrene resin and trimethylammonium-introduced silica.

Immobilized aminoacylase

An immobilized aminoacylase preparation is obtained by adsorbing tannin on a water-insoluble, hydrophilic carrier to give a water-insoluble tannin preparation, adsorbing aminoacylase on the tannin preparation to give a water-insoluble tannin-aminoacylase preparation, and then binding ferric or ferrous ion thereto. The immobilized preparation obtained above sustains a high rate of enzymatic activity for a long period of time when used in an enzymatic reaction thereof with N-acyl-DL-amino acids.

A water-insoluble tannin preparation is obtained by covalent binding or physical adsorption of tannin onto a water-insoluble, hydrophilic carrier. The preparation has a specific affinity for proteins and can be used as an adsorbent for purification, isolation and/or separation of proteins (e.g., Enzymes, albumin, globulin, hormonal proteins) from a mixture of compounds. Further, the water-insoluble tannin preparation having a catalytically active enzyme absorbed thereon can be used as a heterogeneous catalyst to induce enzymatic reactions.

Water-insoluble tannin preparation for immobilization of proteins

A blood purification means whereby blood of a patient to be treated is led around an external circuit connecting to the patient's blood stream and is brought into direct or indirect contact with a fumarate solution, and is further brought into direct or indirect contact with an enzymic preparation, which is suitably an aspartase preparation, which catalyzes a reaction of L-aspartic acid formation from fumaric acid and ammonia. The purification means may further include a preliminary stage or stages whereat an unrequired substance in a patient's blood is decomposed to a non toxic substance and ammonia subsequently convertable to aspartic acid, and may also include a low molecular sieve means preventing re-entry of aspartic acid produced into the patient's blood stream.

Growing community of inventors

Takatsuki, Japan

Takao Mori